Ken Getz, the founder of CenterWatch—a clinical trials information services company—along with private equity investors has purchased the company from Jobson Medical Information. The acquisition was completed in April.
Getz founded CenterWatch in 1994 and established the company as a provider of operating and business information on the $40 billion global clinical trials industry. Getz sold the company to the Thomson Corporation in 1998. CenterWatch was subsequently sold to Jobson Medical Information in 2007.
“I am very excited to have CenterWatch back,” said Getz. “We have plans to modify and improve our print- and web-based publications and services while adding new offerings to assist investigative sites, pharmaceutical and biotechnology companies, contract research organizations and other service providers in being better informed, more effective and successful.”
The May issue of The CenterWatch Monthly newsletter features results and analysis of the 2010 Survey of Investigative Sites in Europe.
Getz is the Chairman of CISCRP—a nonprofit organization that he founded to educate and raise public awareness of the clinical research enterprise—and a Senior Research Fellow at the Tufts Center for the Study of Drug Development where he studies R&D management and operating models, investigative site, outsourcing, and study volunteer trends and policies.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.